Gain Therapeutics, Inc. SEC filings GANX
Gain Therapeutics, Inc. has 240 filings in SEC EDGAR's recent list, going back to Jul 30, 2020. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 28, 2026 (officer or director change). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| UPLOAD | Letter from the SEC | Jun 4, 2025 | — |
| EFFECT | Filing | Dec 29, 2023 | — |
| CORRESP | Letter to the SEC | Dec 22, 2023 | — |
| UPLOAD | Letter from the SEC | Dec 21, 2023 | — |
| EFFECT | Filing | Jun 1, 2022 | — |
| CORRESP | Letter to the SEC | May 31, 2022 | — |
| UPLOAD | Letter from the SEC | May 20, 2022 | — |
| EFFECT | Filing | Mar 17, 2021 | — |
| CERT | Filing | Mar 17, 2021 | — |
| 8-A12B | Form 8-a12b | Mar 17, 2021 | — |
| CORRESP | Letter to the SEC | Mar 16, 2021 | — |
| UPLOAD | Letter from the SEC | Mar 16, 2021 | — |
| CORRESP | Letter to the SEC | Mar 15, 2021 | — |
| CORRESP | Letter to the SEC | Mar 15, 2021 | — |
| CORRESP | Letter to the SEC | Mar 15, 2021 | — |
| UPLOAD | Letter from the SEC | Mar 12, 2021 | — |
| CORRESP | Letter to the SEC | Mar 10, 2021 | — |
| UPLOAD | Letter from the SEC | Feb 23, 2021 | — |
| CORRESP | Letter to the SEC | Feb 19, 2021 | — |
| UPLOAD | Letter from the SEC | Feb 3, 2021 | — |
| DRSLTR | Filing | Jan 29, 2021 | — |
| DRS/A | Filing | Jan 29, 2021 | — |
| UPLOAD | Letter from the SEC | Jan 19, 2021 | — |
| DRSLTR | Filing | Jan 8, 2021 | — |
| DRS/A | Filing | Jan 8, 2021 | — |
| UPLOAD | Letter from the SEC | Dec 14, 2020 | — |
| DRSLTR | Filing | Nov 16, 2020 | — |
| DRS | Filing | Nov 16, 2020 | — |
| D | Filing | Jul 30, 2020 | — |
Showing 29 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- GANX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Bethesda, MD
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1819411
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.